CPX-351

liposomal daunorubicin/cytarabine · Jazz Pharmaceuticals

Drug timelines are a Plus or Pro feature.

21 regulatory and trial events tracked for CPX-351, covering 2012-05-17 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

See pricing